Effect of ABT-335 (fenofibric acid) on meal-induced oxidative stress in patients with metabolic syndrome

ABT-335 therapy reduced fasting and postprandial triglycerides in patients with metabolic syndrome. Autologous HDL may be dysfunctional in these patients as co-incubation with HDL failed to reduce oxidative susceptibility of LDL. During ABT-335 therapy, LDL was less susceptible to Cu++-mediated oxidative modification, in spite of the lack of changes in LDLc levels.